55种药品拟纳入第11批集采范围 国家医保局提示投标企业理性报价

Core Insights - The National Healthcare Security Administration (NHSA) is optimizing drug procurement measures to ensure clinical stability, quality assurance, and to prevent collusion and unhealthy competition in the pharmaceutical industry [1][2] - The 11th batch of national drug procurement will include 55 drug varieties, with an average of 15 companies per drug, indicating a competitive environment [1] - The NHSA has revised procurement rules to avoid a simple lowest price reference, requiring the lowest bidders to justify their pricing and ensure it does not fall below cost [1][2] Group 1 - The NHSA's new measures aim to curb the vicious price competition that has previously pressured companies to lower prices below cost, impacting their profitability and innovation [2] - The changes are expected to shift the focus of pharmaceutical companies from price wars to improving drug quality and fostering research and development [2] - The NHSA plans to draft procurement documents and verify the qualifications and relationships of bidding companies in the next steps of the procurement process [2]